Recipients of donation after circulatory determination of death (DCDD) liver transplants historically have an increased risk of graft failure. Antibody induction (AI) with antiâ€thymocyte globulin (ATG) or antiâ€IL2 receptor (antiâ€ILâ€2R) immunotherapy may decrease the incidence of graft failure by mitigating ischemia reperfusion injury.
|